Catabasis Pharmaceuticals Receives $32,400,000 Series B Financing

  • Feed Type
  • Date
    11/14/2013
  • Company Name
    Catabasis Pharmaceuticals
  • Mailing Address
    One Kendall Square Bldg. 1400E Cambridge, MA 02139
  • Company Description
    At Catabasis we are dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases. We have assembled a team of highly motivated and experienced scientists who are committed to improving the lives of patients.
  • Website
    http://www.catabasispharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $32,400,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Catabasis plans to use proceeds from this financing to support the development of its lead compound, CAT-2003, a modulator of the lipid synthesis pathway, which is currently in a Phase 2 clinical trial in patients with hypertriglyceridemia and in combination with statins in patients with hypercholesterolemia. Catabasis also plans to use the proceeds to support the continued clinical and pre-clinical development of other SMART Linker conjugates in the pipeline.
  • M&A Terms
  • Venture Investor
    Lightstone Ventures
  • Venture Investor
    SV Life Sciences
  • Venture Investor
    Clarus Ventures
  • Venture Investor
    MedImmune Ventures
  • Venture Investor
    Advanced Technology Ventures

Trending on Xconomy